Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatio

Not Applicable

• Conditions: lung adenocarcinoma

• Registration Number: JPRN-UMIN000004807
• Lead Sponsor: KantoKoshinetsu lung cancer research group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-29
• Study Completion: 2015-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

(1) patients who has interstitial pneumonia identified by chest CT or by blood test (2) (3) Patients with EGFR mutation (T790M) which is NOT expected the good response with gefitinib. (4) Patients with uncontrollable complications (5) Pregnant or lactation women, or women with known or suspected pregnancy (6) Patients with severe malabsorption syndrome or with severe functional gastrointestinal disorder (7) patients with systemic administration steroids over 4 weeks (8) Patients with contraindication of gefitinib (9) Patients with active concomitant malignancy (10) Inappropriate patients for this study judged by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified